Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Breast Neoplasms 12Neoplasms 4Recurrence 3Squamous Cell Carcinoma of Head and Neck 2Neoplasms by Site 2Neoplasm Metastasis 2Head and Neck Neoplasms 2Endometrial Neoplasms 2Breast Diseases 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Triple Negative Breast Neoplasms 1Spinal Cord Neoplasms 1Recurrent Ovarian High Grade Serous Adenocarcinoma 1Ovarian Neoplasms 1Neurofibromatosis 1 1Neoplasms, Squamous Cell 1Multiple Myeloma 1Meningioma 1Lymphoma, Non-Hodgkin 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1Liposarcoma 1Hereditary Sensory and Autonomic Neuropathies 1HR+/HER2- Breast Cancer 1Glioma 1Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1Central Nervous System Neoplasms 1Central Nervous System Diseases 1Brain Diseases 1

Interventions

fludarabine phosphate 1fludarabine 1abemaciclib 1Cyclophosphamide 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Squamous Cell × abemaciclib × 30 days × Clear all
NCT04169074 2026-05-22

Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)

University of Arizona

Phase 2 Terminated
7 enrolled 14 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡